|
Finasteride NDSRI
|
|
2
|
172
|
June 15, 2026
|
|
Advancing Generic Drug Development: Translating Science to Approval 2025
|
|
3
|
532
|
June 11, 2026
|
|
Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop
|
|
6
|
380
|
June 8, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
155
|
June 8, 2026
|
|
Upcoming EMA Q&A for other nitrosocompounds
|
|
3
|
466
|
June 5, 2026
|
|
The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines -Pub
|
|
0
|
91
|
June 3, 2026
|
|
👨💻 Expand the analytical toolkit for comprehensive detection of nitrosamines using SIFT-MS
|
|
0
|
125
|
June 2, 2026
|
|
An updated version of Health Canada's Guidance on nitrosamine impurities in medications(Update May 29, 2026)
|
|
0
|
309
|
June 2, 2026
|
|
MS Method Development Criterias?
|
|
1
|
175
|
June 2, 2026
|
|
For anyone attending AAPS Summer Scientific Forum
|
|
1
|
134
|
June 1, 2026
|
|
Analysis of Nitrite in Pharmaceutical Excipients: A Multi‑Laboratory Comparative Study - PUB
|
|
3
|
468
|
June 1, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
450
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
297
|
June 1, 2026
|
|
Published limit for N-Nitroso-Vonoprazan
|
|
3
|
509
|
May 29, 2026
|
|
📣 Theoretical and Experimental Assessment of Nitrosamine Risk in Industrial Solvent Recovery -Pub
|
|
3
|
534
|
May 29, 2026
|
|
Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products -Pub
|
|
4
|
400
|
May 27, 2026
|
|
Why EMA still assigns AI limits (CPCA) for nitrosamines in oncology drugs
|
|
7
|
463
|
May 27, 2026
|
|
Solution stability of NDSRI
|
|
8
|
403
|
May 25, 2026
|
|
Nitrite in Amines
|
|
15
|
1025
|
May 21, 2026
|
|
N-Nitroso Perindopril Limit as NMI or 1500ng/day
|
|
3
|
258
|
May 21, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
112
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2950
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
102
|
May 20, 2026
|
|
Liquid Chromatography–High-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
86
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
132
|
May 20, 2026
|
|
🇰🇷 MFDS Guideline: Compilation of Analysis Methods on the Determination of Impurities in Pharmaceuticals, May-2026
|
|
2
|
300
|
May 19, 2026
|
|
Source of N-nitroso-n-methylaniline (NMPA)
|
|
7
|
347
|
May 19, 2026
|
|
Regulatory Rationale for Restricting LTL Application to Nitrosamines
|
|
4
|
486
|
May 19, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1211
|
May 18, 2026
|
|
Science-led approaches to nitrosamine qualification and safety assessment-webinar
|
|
1
|
223
|
May 15, 2026
|